5HT通过减弱肺腺癌中的铁死来调节对奥莫尔蒂尼布的耐药性.
在PubMed上查看摘要
概括
此摘要是机器生成的。在肺癌中,HER2 S310F突变通过增加5-HT而导致EGFR- TKI治疗的耐药性. 使用像palonosetron这样的抗体向5-HT3受体可能会恢复药物敏感性.
科学领域
- 癌症学
- 分子生物学
- 药理学
背景情况
- 皮肤生长因子受体 (EGFR) - 铁酶抑制剂 (TKI) 耐药性是治疗EGFR突变肺腺癌 (LUAD) 的一个主要障碍.
- 需要个性化治疗策略来克服抵抗机制.
- HER2 S310F突变已成为第三代EGFR- TKI耐药性的因素.
研究的目的
- 调查HER2 S310F突变和5-三胺 (5-HT) 在LUAD中的EGFR-TKI耐药性的作用.
- 确定潜在的治疗策略来逆转阿莫尔蒂尼布的耐药性.
- 探索5-HT水平在EGFR-TKI耐药性的预测价值.
主要方法
- 药物库查和转录组学分析以确定耐药性机制.
- 研究5-HT/5-HT3受体/Ca2+/CAMKK2/AMPK通路.
- 测试HTR3抗剂,特别是palonosetron与auomolertinib联合使用的疗效.
- 测量患者血中的5-HT水平.
主要成果
- HER2 S310F突变通过5-HT积累驱动aumolertinib耐药性,这激活了Ca2+/ CAMKK2/ AMPK通路,从而赋予了铁死耐药性.
- 确定了5-HT3受体 (HTR3) 抗剂,如palonosetron,作为克服 aumolertinib 耐药性的潜在药物.
- 对5-HT/ HTR3信号通路的药理向恢复了对auomolertinib的敏感性.
- 血5-HT水平升高可能预示着LUAD患者的EGFR-TKI耐药性.
结论
- 在LUAD中,5-HT/ ferroptosis轴对 aumolertinib 耐药性起着至关重要的作用.
- 在Aumolertinib治疗的LUAD患者中,HTR3抗剂是一个有前途的新组合治疗策略.
- 血5-HT水平可以作为EGFR-TKI耐药性的预测生物标志物.
相关概念视频
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

